Article Text
Therapeutics/Prevention
Randomised controlled trial
Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis
Statistics from Altmetric.com
Commentary on: OpenUrl
Context
Despite the increasing number of effective disease modifying therapies for multiple sclerosis (MS), there are no effective therapies for the progressive, neurodegenerative phase of the disease. There is now abundant experimental evidence that cannabinoids and the endocannabinoid system are protective factors in animal models of MS and also other neurodegenerative conditions. This randomised controlled trial (RCT) aimed to investigate the potential neuroprotective properties of the prototypical cannabinoid Δ 9-tetrahydrocannabinol (THC) as measured by the slowing of the progressive phase …